<DOC>
	<DOC>NCT01721564</DOC>
	<brief_summary>6 months therapy of Bosentan, an endothelin antagonist, will lead to improvement in pulmonary microvascular endothelial function.</brief_summary>
	<brief_title>Bosentan and Pulmonary Endothelial Function</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Pulmonary arterial hypertension; idiopathic and connective tissue disease associated Confirmed or invasive haemodynamic: Mean pulmonary arterial pressure greater than or equal to 25 millimeters of mercury Pulmonary capillary wedge pressure less than 15 millimeters of mercury No prior pulmonary hypertension specific therapy Ability to provide informed consent Contraindications to medications used to test endothelial function; acetylcholine, sodium nitroprusside, NGMonomethylLArginine, Larginine Advanced renal disease Previous allergic reaction to contrast agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>